Scleroderma Induced by Pembrolizumab

A Case Series

Naiara S. Barbosa, David A. Wetter, Carilyn N. Wieland, Niraj K. Shenoy, Svetomir Nenad Markovic, Uma Thanarajasingam

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.

Original languageEnglish (US)
Pages (from-to)1158-1163
Number of pages6
JournalMayo Clinic Proceedings
Volume92
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Melanoma
Limited Scleroderma
Diffuse Scleroderma
Immune Tolerance
Autoimmune Diseases
Therapeutics
Survival
pembrolizumab
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Scleroderma Induced by Pembrolizumab : A Case Series. / Barbosa, Naiara S.; Wetter, David A.; Wieland, Carilyn N.; Shenoy, Niraj K.; Markovic, Svetomir Nenad; Thanarajasingam, Uma.

In: Mayo Clinic Proceedings, Vol. 92, No. 7, 01.07.2017, p. 1158-1163.

Research output: Contribution to journalArticle

Barbosa, Naiara S. ; Wetter, David A. ; Wieland, Carilyn N. ; Shenoy, Niraj K. ; Markovic, Svetomir Nenad ; Thanarajasingam, Uma. / Scleroderma Induced by Pembrolizumab : A Case Series. In: Mayo Clinic Proceedings. 2017 ; Vol. 92, No. 7. pp. 1158-1163.
@article{4bf88fe9fb2743afa29a3f0b6d93e0af,
title = "Scleroderma Induced by Pembrolizumab: A Case Series",
abstract = "Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.",
author = "Barbosa, {Naiara S.} and Wetter, {David A.} and Wieland, {Carilyn N.} and Shenoy, {Niraj K.} and Markovic, {Svetomir Nenad} and Uma Thanarajasingam",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.mayocp.2017.03.016",
language = "English (US)",
volume = "92",
pages = "1158--1163",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "7",

}

TY - JOUR

T1 - Scleroderma Induced by Pembrolizumab

T2 - A Case Series

AU - Barbosa, Naiara S.

AU - Wetter, David A.

AU - Wieland, Carilyn N.

AU - Shenoy, Niraj K.

AU - Markovic, Svetomir Nenad

AU - Thanarajasingam, Uma

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.

AB - Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.

UR - http://www.scopus.com/inward/record.url?scp=85020182824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020182824&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2017.03.016

DO - 10.1016/j.mayocp.2017.03.016

M3 - Article

VL - 92

SP - 1158

EP - 1163

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 7

ER -